Unlock instant, AI-driven research and patent intelligence for your innovation.

Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same

The dual vaccine formulation of recombinant PsaA protein conjugated with N. meningitidis capsular polysaccharide serogroup C addresses the limitations of current vaccines by enhancing immunogenicity and providing broad protection against S. pneumoniae and N. meningitidis, improving accessibility and reducing costs.

Inactive Publication Date: 2012-01-12
TAI STANLEY SHIH PENG +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The conjugated vaccine significantly increases immunogenicity, providing dual protection against S. pneumoniae and N. meningitidis infections, is cost-effective, and accessible to developing countries, reducing the economic and medical burden of pneumococcal and meningococcal diseases.

Problems solved by technology

Antibodies raised for one serotype do not provide protection against infection of other serotypes.
The efficacy of the 23-valent vaccine is limited.
Furthermore, PS is a T-cell independent antigen which induces short-term immunity without immune memory and is not effective in children younger than two years of age (Greenwood B M et al., Trans R Soc Trop Med Hyg, 1980, 74:756-760).
It is only prescribed for use in the prevention of pediatric invasive pneumococcal disease because of its high cost and limited supply.
The drawback of these two families of vaccines is that they only provide protection against infection by the specific serotypes of S. pneumoniae that are included in the respective vaccine formulations.
It is expensive and not affordable for developing countries.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example

[0048]A better understanding of the vaccine provided herein and its many advantages is provided with the following example.

A. Preparation of Purified rPsaA

[0049]psaA gene cloning and expression. To prepare recombinant pneumococcal PsaA (rPsaA) protein, the coding sequence of pneumococcal psaA genes in E. coli was cloned in the expression vector pET22b(+) (Novagen, Madison, Wis.). Sequence analysis revealed that the coding sequence of psaA does not include BamHI and HindIII restriction sites. For the purpose of cloning, expression, and purification of rPsaA protein, a pair of primers for PCR amplification were designed so that: 1) the PCR product would have a BamHI and HindIII site at the 5′ and 3′ ends, respectively; 2) the reading frame of cloned psaA would be in-frame with that of the vector; and 3) the produced rPsaA protein would have a His-tag at its C-terminal. The forward and reverse primers (5′-GGGATCCTAGCGGAAAAAAAGATACA-3′ (SEQ ID NO. 3), 5′-GCAAGCTTTGCCAATCCTTCAGCAATC-3′ (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.

Description

[0001]The present application is a continuation of U.S. application Ser. No. 12 / 425,232, filed Apr. 16, 2009, which is incorporated herein by reference.FIELD OF THE INVENTION[0002]This disclosure relates to vaccine formulations that include an immunogenic composition for inducing antibodies to the S. pneumoniae PsaA protein and N. meningitidis capsular polysaccharide. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.BACKGROUND OF THE INVENTION[0003]Status of current pneumococcal vaccines. S. pneumoniae is a gram-positive encapsulated diplococcus. Capsule, a layer of polysaccharide (PS) surrounding the bacterial cell, is a major virulence factor of S. pneumoniae. Based on the differences in structure and immunological response to capsular polysaccharide, S. pneumoniae can be divided into more than 90 different serotypes. Capsular polysaccharides are the base for the currently used vaccines. The FDA has approved two ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/385A61P31/04
CPCA61K2039/6068A61K39/095Y10S424/831A61P31/04A61P37/04A61K39/092A61K2039/70
Owner TAI STANLEY SHIH PENG
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com